Niagen Bioscience Resultados de beneficios anteriores
Pasado controles de criterios 4/6
Niagen Bioscience ha aumentado sus beneficios a una tasa media anual de 68.9%, mientras que los beneficios de la industria de Personal Products han experimentado un descenso de 0.01% anual. Los ingresos han ido creciendo a una tasa media de 15.9% al año. La rentabilidad financiera de Niagen Bioscience es de 22.6%, y sus márgenes netos son de 14.3%.
Información clave
68.94%
Tasa de crecimiento de los beneficios
69.29%
Tasa de crecimiento del BPA
| Crecimiento de la industria Personal Products | 20.87% |
| Tasa de crecimiento de los ingresos | 15.87% |
| Rentabilidad financiera | 22.64% |
| Margen neto | 14.29% |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • May 14
NAGE: Core Demand And Injectables Will Drive Future Upside Potential
Niagen Bioscience's analyst price target has shifted from $13.60 to $12.60, as analysts adjust their models to slightly lower revenue growth, profit margin, and fair value assumptions while still highlighting ongoing demand in the core business and potential upside from the injectable segment. Analyst Commentary Recent research updates show a consistent pattern of price target reductions, with the latest move taking the blended target to US$12.60.Actualización de narrativa • Apr 22
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that point to steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Recent commentary around Niagen Bioscience centers on how updated Q4 models affect the risk and reward trade off, with attention on both the established core business and the injectable opportunity.Actualización de narrativa • Apr 07
NAGE: Core Strength And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that reflect steady demand in the core business and possible upside from the injectable segment. Analyst Commentary Analysts see the updated price target as largely reflecting model clean up after Q4, rather than a shift in the overall view on the business.Actualización de narrativa • Mar 23
NAGE: Core Demand And Injectables Will Support Future Upside Potential
Analysts have trimmed their price target on Niagen Bioscience to $13 from $14. This reflects updated models after Q4 results that pointed to steady demand in the core business and potential upside from the injectable segment.Actualización de narrativa • Mar 06
NAGE: Core Demand And Injectables Outlook Will Support Future Upside
Analysts have trimmed their 12 month price target on Niagen Bioscience from $16.04 to $13.60, citing updated models that reflect steady demand in the core business, potential upside in injectables, adjustments to revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to steady demand in the core business as a key support for current valuation, suggesting the updated models still see the existing portfolio as a meaningful earnings driver.Seeking Alpha • Nov 15
Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years
Summary Niagen Bioscience delivered record Q3 revenue, rising 33% year-over-year, driven by strong Tru Niagen demand and accelerating distribution partnerships. Gross margin expanded to 64.5%, while operating income and adjusted EBITDA grew sharply, reflecting improving scale and cost discipline. Cash from operations already exceeded last year’s total, supporting a new $10 million share repurchase program. The FDA’s reversal on NMN introduces meaningful uncertainty for future demand and competitive dynamics in the NAD+ category. Niagen Bioscience remains financially strong, but sustained momentum in a post-NMN market is unproven, warranting a hold rating. Read the full article on Seeking AlphaArtículo de análisis • Nov 11
We Think Niagen Bioscience's (NASDAQ:NAGE) Profit Is Only A Baseline For What They Can Achieve
Even though Niagen Bioscience, Inc. ( NASDAQ:NAGE ) posted strong earnings, investors appeared to be underwhelmed. We...Artículo de análisis • Nov 07
Niagen Bioscience, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) just released its quarterly report and things are looking bullish. The company...Artículo de análisis • Oct 03
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 25% Cheaper Price Remains In Tune With Revenues
To the annoyance of some shareholders, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares are down a considerable 25% in...Nueva narrativa • Aug 25
Wellness Adoption And Academic Trials Will Define Future Opportunity
Key Takeaways Expanding clinical credibility and global partnerships are opening new high-margin markets, broadening channels, and supporting scalable revenue growth with improved margins. Strong e-commerce performance and diversified product pipeline in preventive health provide resilience, reduced risk, and durable long-term earnings visibility.Actualización de narrativa • Aug 08
Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects
Upward revisions to Niagen Bioscience's price target reflect positive clinical trial results confirming both safety and significant efficacy of its NAD+ supplementation, increased market confidence, and ongoing product and sales momentum, resulting in a higher consensus analyst price target rising from $14.90 to $15.84. Analyst Commentary Positive clinical study results published in a peer-reviewed journal demonstrated that Niagen Bioscience’s NAD+ supplementation is safe for patients with Werner syndrome and achieved a ~140% increase in blood NAD+ levels, along with improvements in liver, kidney, and arterial health markers.Artículo de análisis • Aug 08
Niagen Bioscience, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...Artículo de análisis • Aug 06
What You Can Learn From Niagen Bioscience, Inc.'s (NASDAQ:NAGE) P/S After Its 28% Share Price Crash
NasdaqCM:NAGE 1 Year Share Price vs Fair Value Explore Niagen Bioscience's Fair Values from the Community and select...Artículo de análisis • Jun 17
Market Participants Recognise Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Revenues Pushing Shares 29% Higher
Niagen Bioscience, Inc. ( NASDAQ:NAGE ) shares have continued their recent momentum with a 29% gain in the last month...Artículo de análisis • May 10
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
A week ago, Niagen Bioscience, Inc. ( NASDAQ:NAGE ) came out with a strong set of first-quarter numbers that could...Artículo de análisis • Apr 05
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues
The Niagen Bioscience, Inc. ( NASDAQ:NAGE ) share price has softened a substantial 30% over the previous 30 days...Artículo de análisis • Mar 29
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE)
Key Insights Niagen Bioscience's estimated fair value is US$7.18 based on 2 Stage Free Cash Flow to Equity Niagen...
Nueva narrativa • Feb 09
NIAGEN IV Expansion And FDA Approvals Will Unlock Future Opportunities
Expansion in clinics and strategic partnerships support revenue growth through increased e-commerce and pharmaceutical-grade product sales.Artículo de análisis • Nov 07
ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors
ChromaDex Corporation's ( NASDAQ:CDXC ) strong earnings report was rewarded with a positive stock price move. We did...Artículo de análisis • Nov 05
Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%
Despite an already strong run, ChromaDex Corporation ( NASDAQ:CDXC ) shares have been powering on, with a gain of 70...Artículo de análisis • Jul 25
ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company
Those holding ChromaDex Corporation ( NASDAQ:CDXC ) shares would be relieved that the share price has rebounded 25% in...Artículo de análisis • Jun 15
Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable
Key Insights ChromaDex's Annual General Meeting to take place on 20th of June Total pay for CEO Rob Fried includes...Artículo de análisis • Jun 05
Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump
ChromaDex Corporation ( NASDAQ:CDXC ) shares have retraced a considerable 26% in the last month, reversing a fair...Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Niagen Bioscience. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 130 | 19 | 66 | 7 |
| 31 Dec 25 | 129 | 17 | 63 | 6 |
| 30 Sep 25 | 125 | 20 | 54 | 6 |
| 30 Jun 25 | 116 | 18 | 52 | 5 |
| 31 Mar 25 | 108 | 14 | 49 | 5 |
| 31 Dec 24 | 100 | 9 | 48 | 6 |
| 30 Sep 24 | 92 | 1 | 50 | 6 |
| 30 Jun 24 | 86 | -1 | 49 | 6 |
| 31 Mar 24 | 83 | -4 | 49 | 6 |
| 31 Dec 23 | 84 | -5 | 51 | 5 |
| 30 Sep 23 | 83 | -6 | 52 | 5 |
| 30 Jun 23 | 81 | -6 | 52 | 5 |
| 31 Mar 23 | 77 | -11 | 54 | 5 |
| 31 Dec 22 | 72 | -17 | 57 | 5 |
| 30 Sep 22 | 69 | -20 | 60 | 5 |
| 30 Jun 22 | 69 | -28 | 66 | 4 |
| 31 Mar 22 | 70 | -27 | 66 | 4 |
| 31 Dec 21 | 67 | -27 | 65 | 4 |
| 30 Sep 21 | 65 | -28 | 65 | 4 |
| 30 Jun 21 | 62 | -23 | 59 | 4 |
| 31 Mar 21 | 60 | -21 | 55 | 3 |
| 31 Dec 20 | 59 | -20 | 52 | 3 |
| 30 Sep 20 | 57 | -23 | 51 | 4 |
| 30 Jun 20 | 55 | -26 | 52 | 4 |
| 31 Mar 20 | 51 | -30 | 52 | 4 |
| 31 Dec 19 | 46 | -32 | 53 | 4 |
| 30 Sep 19 | 42 | -32 | 49 | 5 |
| 30 Jun 19 | 38 | -33 | 48 | 5 |
| 31 Mar 19 | 35 | -33 | 46 | 5 |
| 31 Dec 18 | 32 | -33 | 44 | 5 |
| 30 Sep 18 | 30 | -34 | 43 | 6 |
| 30 Jun 18 | 28 | -29 | 37 | 5 |
| 31 Mar 18 | 24 | -23 | 29 | 5 |
| 30 Dec 17 | 21 | -17 | 22 | 4 |
| 30 Sep 17 | 18 | -10 | 14 | 3 |
| 01 Jul 17 | 16 | -8 | 11 | 3 |
| 01 Apr 17 | 18 | -6 | 11 | 3 |
| 31 Dec 16 | 22 | -4 | 11 | 3 |
| 01 Oct 16 | 22 | -3 | 10 | 2 |
| 02 Jul 16 | 24 | -2 | 10 | 2 |
| 02 Apr 16 | 24 | -1 | 10 | 1 |
| 02 Jan 16 | 18 | -3 | 9 | 1 |
| 03 Oct 15 | 22 | -3 | 9 | 1 |
| 04 Jul 15 | 20 | -3 | 9 | 1 |
Ingresos de calidad: NAGE tiene una única gran ganancia de $6.8M que afecta a sus resultados financieros de los últimos 12 meses de 31st March, 2026.
Margen de beneficios creciente: Los actuales márgenes de beneficio (14.3%) de NAGE son superiores a los del año pasado (13.1%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: NAGE ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 68.9% al año.
Acelerando crecimiento: El crecimiento de los beneficios de NAGE en el último año (32.1%) está por debajo de su media de 5 años (68.9% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de NAGE en el último año (32.1%) superó al de la industria Personal Products -21.6%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera (22.6%) de NAGE se considera alta.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 09:00 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Niagen Bioscience, Inc. está cubierta por 8 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jeffrey Van Sinderen | B. Riley Securities, Inc. |
| Susan Anderson | Canaccord Genuity |
| Jeffrey Mark | Farmhouse Equity Research |